Skip to content

LUMOS PHARMA, INC.

CIK 0001126234

← back to feed
Revenue (TTM)
$1.39M
+34.7% YoY Q3 Nov 2024
Net Income (TTM)
−$33.76M
−9.6% YoY Q3 Nov 2024
EPS Diluted (TTM)
−$4.16
−12.7% YoY Q3 Nov 2024
Gross Margin
—
Q3 Nov 2024
Operating Margin
-2,543.8%
Q3 Nov 2024
Net Margin
-2,435.7%
Q3 Nov 2024
Free Cash Flow (TTM)
−$41.59M
Q3 Nov 2024
Cash
$13.52M
Q3 Nov 2024
Total Debt
$617K
Q3 Nov 2024
Shares Outstanding
8.65M sh
Q3 Nov 2024

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings